Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials: Journal – CGTN
The potential vaccine appeared to be safe and can trigger an immune response.
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The candidate has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Sinopharm is testing the potential vaccine in the United Arab Emirates in a Phase 3 tria…
-
General22 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
General23 hours agoLithium mine closure shines light on Ravensthorpe community’s resilience
-
Noosa News21 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
General24 hours agoBack-to-back rate cuts tipped when Reserve Bank meets